Assessment of prevalence and changing epidemiology of extended-spectrum beta-lactamase-producing Enterobacteriaceae fecal carriers using a chromogenic medium

Diagnostic Microbiology and Infectious Disease
Raquel PaniaguaR Cantón

Abstract

Five hundred fecal samples from 462 patients (68.4% ambulatory) (February-April, 2007) from Madrid (Spain) were screened for extended-spectrum beta-lactamase (ESBL) producers using ceftazidime and cefotaxime (1 mg/L) MacConkey (MAC) agar plates and a chromogenic media (chromID ESBL; bioMérieux, Marcy-l'Etoile, France). bla(ESBL), qnr, aac(6')Ib-cr, and 16S rRNA methylase genes were assessed. A prevalence of 8.2% of ESBL fecal carriers was observed (8.9% hospitalized, 7.9% nonhospitalized patients), higher than that previously observed (1991, 0.6%; 2003, 7.0%). Sensitivity, specificity, and positive and negative predicted values were 100%, 94.8%, 63%, and 100% for chromID ESBL and 87.8%, 89.8%, 43.4%, and 98.9% for MAC, respectively. ESBL distribution was as follows: CTX-M-9-group, 40% (mainly CTX-M-14); CTX-M-1-group, 26.6% (mainly CTX-M-15); SHV-type, 29% (mainly SHV-12); and TEM-type, 4.4%. These enzymes were found in pulsed-field gel electrophoresis nonclonally related Escherichia coli and Klebsiella pneumoniae isolates. Transferable quinolone resistance was confirmed in CTX-M-9 (qnrS1), CTX-M-15 [aac(6')Ib-cr, qnrS1], and SHV-12 (qnrB7, qnrS1) producers but not 16S rRNA methylase genes. The chromID ESBL medium was reliable ...Continue Reading

References

Jun 8, 2007·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Yohei Doi, Yoshichika Arakawa
Jun 15, 2007·The Journal of Antimicrobial Chemotherapy·Vincent CattoirPatrice Nordmann

❮ Previous
Next ❯

Citations

Feb 2, 2011·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Umaer Naseer, Arnfinn Sundsfjord
Aug 13, 2011·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Haeng Soon JeongJeong Nyeo Lee
Jan 20, 2012·Journal of Clinical Microbiology·Muriel GazinUNKNOWN MOSAR WP2 and SATURN WP1 Study Teams
Feb 18, 2014·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·M SoléJ Vila
Jan 16, 2013·Scandinavian Journal of Infectious Diseases·Alice BarsoumianKevin S Akers
May 27, 2014·International Journal of Medical Microbiology : IJMM·Cristina Belmar CamposMoritz Hentschke
Sep 15, 2017·Indian Journal of Critical Care Medicine : Peer-reviewed, Official Publication of Indian Society of Critical Care Medicine·Shalini Shenoy MulkiSevitha Bhat

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.